RayKnowChina Research Map
Shortlist

UrumqiXinjiang Medical University

First Affiliated Hospital of Xinjiang Medical University

新疆医科大学第一附属医院

Listed for 13 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at First Affiliated Hospital of Xinjiang Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌29 papers led
  2. Hepatocellular carcinoma肝细胞癌22 papers led
  3. Retinoblastoma视网膜母细胞瘤1 paper led
  4. Osteosarcoma骨肉瘤2 papers led
  5. Multiple myeloma多发性骨髓瘤3 papers led
  6. Aplastic anaemia再生障碍性贫血2 papers led
  7. Takayasu arteritis大动脉炎0 papers led
  8. Hepatic echinococcosis肝包虫病43 papers led
  9. Idiopathic pulmonary fibrosis特发性肺纤维化0 papers led
  10. Behçet disease白塞病1 paper led
  11. IgA nephropathyIgA 肾病0 papers led
  12. Osteogenesis imperfecta成骨不全症0 papers led
  13. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led

Not listed for: Nasopharyngeal carcinoma, Stomach cancer, Hepatoblastoma, Chordoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 29 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 1.0%.

Papers led
29
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 6620222023: 5520232024: 6620242025: 882025

2 hospitals in Urumqi for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesMolecular markers & genomicsImmunotherapyRadiotherapy
Departments in papersPathology / laboratory medicineGastroenterology / hepatologyMedical oncology

Over half of these papers are lab or animal studies.

Papers it led29
  1. 5-FU Resistance Facilitates Immune Evasion in Esophageal Squamous Cell Carcinoma Through ADAM10-Mediated PD-L1 Shedding and Tumour Microenvironment Remodelling.2026Immunology
  2. Prognostic Value of UBE2S, HIF-1α, and FOXM1 Expression in Esophageal Squamous Cell Carcinoma.2025Analytical cellular pathology (Amsterdam)Free full text
  3. Lipidomic and transcriptomic analysis and its therapeutic implications in Chinese Kazakh patients with esophageal squamous cell carcinoma.2025BMC cancerFree full text
  4. PANoptosis-driven molecular stratification in esophageal squamous cell carcinoma: A multi-omics prognostic model and FGFR-Targeted therapeutic validation.2025Computers in biology and medicine
  5. PSD3 as a context-dependent modulator of immune landscape and tumor aggressiveness in esophageal squamous cell carcinoma.2025Frontiers in immunologyFree full text
  6. WISP1 drives esophageal squamous cell carcinoma progression via modulation of cancer-associated fibroblasts and immune microenvironment.2025Frontiers in immunologyFree full text
  7. ZNF468/AURKA/PI3K/AKT Positive Feedback Loop Promotes Proliferation and Metastasis of Oesophageal Squamous Cell Carcinoma.2025Journal of cellular and molecular medicineFree full text
  8. The ferroptotic effect of NRF2-GCLM signaling axis derived by radiotherapy of esophageal squamous cell cancer: the vivo study.2025Scientific reportsFree full text
  9. PSD3, regulated by PKM2, endows growth and metastasis advantages in esophageal squamous cell carcinoma by modulating EMT progression.2025Scientific reportsFree full text
  10. ZNF468 inhibits irradiation-induced G2/M cell cycle arrest and apoptosis by facilitating AURKA transcription in Esophageal Squamous Cell Carcinoma.2024Biochemical and biophysical research communications
  11. Vimentin, inversely correlating with infiltration of CD8 + T lymphocytes, promotes nuclear translocation of PD-L1 in esophageal squamous cell carcinoma.2024Biochimica et biophysica acta. Molecular cell research
  12. Nuclear factor erythroid 2-related factor 2 promotes radioresistance by regulating glutamate-cysteine ligase modifier subunit and its unique immunoinvasive pattern.2024Biomolecules & biomedicineFree full text
  13. Expression and Clinicopathological Significance of Extracellular Matrix Remodeling Markers in Esophageal Squamous Carcinoma.2024Critical reviews in eukaryotic gene expression
  14. Immune cell infiltration and drug sensitivity in PIK3CA-mutated esophageal squamous cell carcinoma: A TCGA database analysis.2024Human immunology
  15. NME4 suppresses NFκB2-CCL5 axis, restricting CD8+ T cell tumour infiltration in oesophageal squamous cell carcinoma.2024Immunology
  16. LEPRE1 shapes a non-flamed tumour immune landscape and predicts the prognosis in esophageal squamous cell carcinoma.2023Clinical and translational medicineFree full text
  17. Prognostic value of Nrf2/HO-1 expression and its correlation with occurrence in esophageal squamous cell carcinoma.2023Genes & genomics
  18. The expression of annexin-A1 in esophageal squamous cell carcinoma and its association with the biological behavior of the primary human esophageal squamous carcinoma cell line.2023Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  19. Construction of a prognostic model for radical esophagectomy based on immunohistochemical prognostic markers combined with clinicopathological factors.2023MedicineFree full text
  20. NRF2/HO-1 axis, BIRC5, and TP53 expression in ESCC and its correlation with clinical pathological characteristics and prognosis.2023The International journal of biological markers
  21. Prognostic Value of GPNMB, EGFR, p-PI3K, and Ki-67 in Patients with Esophageal Squamous Cell Carcinoma.2022Analytical cellular pathology (Amsterdam)Free full text
  22. The Relationship between MACC1/c-Met/Cyclin D1 Axis Expression and Prognosis in ESCC.2022Analytical cellular pathology (Amsterdam)Free full text
  23. Highly Expressing SCARA5 Promotes Proliferation and Migration of Esophageal Squamous Cell Carcinoma.2022Journal of immunology researchFree full text
  24. Establishment of esophageal squamous carcinoma cell lines with different invasive metastatic potential and differential gene screening.2022Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  25. Proteomic profiling of plasma exosomes reveals CD82 involvement in the development of esophageal squamous cell carcinoma.2022Journal of proteomics
  26. Tumor-infiltrating lymphocyte signature in epithelial and stromal compartments of an esophageal squamous cell carcinoma acidic microenvironment mediated by MCT4.2022Pathology, research and practice
  27. CXCL6 fuels the growth and metastases of esophageal squamous cell carcinoma cells both in vitro and in vivo through upregulation of PD-L1 via activation of STAT3 pathway.2021Journal of cellular physiology
  28. Clinical significance of YAP1 and TAZ in esophageal squamous cell carcinoma.2021MedicineFree full text
  29. Plasma‑derived exosomal pyruvate kinase isoenzyme type M2 accelerates the proliferation and motility of oesophageal squamous cell carcinoma cells.2021Oncology reportsFree full text
All its trials on ClinicalTrials.gov, any status1
  1. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
More papers found outside PubMed (not counted)8
  1. Additional file 1 of Lipidomic and transcriptomic analysis and its therapeutic implications in Chinese Kazakh patients with esophageal squamous cell carcinoma2025Figsharearticle
  2. Lipidomic and transcriptomic analysis and its therapeutic implications in Chinese Kazakh patients with esophageal squamous cell carcinoma2025Figsharesupplementary-materials
  3. Vasculogenic mimicry and p53 expression in esophageal squamous cell carcinoma patients of Kazakh ethnicity, the association between vasculogenic mimicry and p53 expression and its influence on prognosis2025International Surgery Journalarticle
  4. Overexpression of CXCL5 promotes proliferation and infiltration of esophageal squamous cell carcinoma2023Research Squarepreprint
  5. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncologyconference-abstract
  6. Correlation Of SOX17, MACC1, c-Met With Clinicopathological Features And Prognosis of Esophageal Squamous Cell Carcinoma2021Research Squarepreprint
  7. Retrospective Analyses of the Clinicopathological and Prognostic Features of Esophageal Squamous Cell Carcinoma in a Grade A Tertiary Hospital in Xinjiang, China2021Venue not listedpreprint
  8. The effect of SOX17, MACC1 and c-Met expression in ESCC on prognosis2021Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 22 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
22
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 4420212022: 101020222023: 1120232024: 1120242025: 552025

1 hospital in Urumqi for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesLocal treatment (ablation, TACE, HAIC)Recurrence & prognosisImaging, AI & early detection
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineGastroenterology / hepatology
Papers it led22
  1. Artificial intelligence-driven CT radiomics model predicts prognosis in TACE-refractory hepatocellular carcinoma.2026Abdominal radiology (New York)Free full text
  2. Structural and temporal dynamics analysis of PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: History, research hotspots, and emerging trends.2025Human vaccines & immunotherapeuticsFree full text
  3. Synergistic and toxicity‑reducing effects of acteoside as an adjuvant therapy of oxaliplatin against hepatocellular carcinoma.2025International journal of oncologyFree full text
  4. An integrated chemokine-based machine learning model predicts prognosis and guides immunotherapy in hepatocellular carcinoma.2025MedicineFree full text
  5. Hepatitis B-associated cirrhosis combined with multiple nodular fatty infiltrates of the liver: A rare benign disease misdiagnosed as hepatocellular carcinoma - a case report.2025MedicineFree full text
  6. METTL14 suppresses the migration and invasion of hepatocellular carcinoma cells by m6A methylation of RPLP2.2025Scientific reportsFree full text
  7. The novel predictive nomograms for early death in metastatic hepatocellular carcinoma: A large cohort study.2024MedicineFree full text
  8. Rapid detection of serological biomarkers in gallbladder carcinoma using fourier transform infrared spectroscopy combined with machine learning.2023Talanta
  9. Natural history of decompensated cirrhosis with serum hepatitis B DNA < 2000 IU/mL: a retrospective study.2022BMC gastroenterologyFree full text
  10. Surgical resection versus radiofrequency ablation for early recurrent hepatocellular carcinoma.2022European journal of gastroenterology & hepatology
  11. Roles of immune cells in the concurrence of Echinococcus granulosus sensu lato infection and hepatocellular carcinoma.2022Experimental parasitology
  12. LncRNA NEAT1 sponges miR-214 to promoted tumor growth in hepatocellular carcinoma.2022Mammalian genome : official journal of the International Mammalian Genome Society
  13. Curative Analysis of Patients with Hepatocellular Carcinoma Using Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation.2022Medical science monitor : international medical journal of experimental and clinical researchFree full text
  14. Repeat hepatic resection VS radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma: an updated meta-analysis.2022Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  15. Upregulated TUBG1 expression is correlated with poor prognosis in hepatocellular carcinoma.2022PeerJFree full text
  16. Urine fluorescence spectroscopy combined with machine learning for screening of hepatocellular carcinoma and liver cirrhosis.2022Photodiagnosis and photodynamic therapy
  17. Urine surface-enhanced Raman spectroscopy combined with SVM algorithm for rapid diagnosis of liver cirrhosis and hepatocellular carcinoma.2022Photodiagnosis and photodynamic therapy
  18. Hsa_circ_0008092 Contributes to Cell Proliferation and Metastasis in Hepatocellular Carcinoma via the miR-502-5p/CCND1 Axis.2022Protein and peptide letters
  19. Vascular normalization therapy with targeted localized vessel bevacizumab infusion in hepatocellular carcinoma after transarterial chemoembolization failure.2021Annals of palliative medicine
  20. MiR-27a-3p enhances the cisplatin sensitivity in hepatocellular carcinoma cells through inhibiting PI3K/Akt pathway.2021Bioscience reportsFree full text
  21. Connexin32 activates necroptosis through Src-mediated inhibition of caspase 8 in hepatocellular carcinoma.2021Cancer scienceFree full text
  22. Mesenchymal stem cell-derived exosomes block malignant behaviors of hepatocellular carcinoma stem cells through a lncRNA C5orf66-AS1/microRNA-127-3p/DUSP1/ERK axis.2021Human cell
Chinese-language papers (not in the count)1
  1. [Analysis of PIKFYVE gene expression, clinical significance, and experimental validation based on TCGA database in hepatocellular carcinoma].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status4
  1. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  2. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  3. Prospective Surveillance for Very Early Hepatocellular CarcinomaStatus unknownNCT03588442Study siteStart 2018-07
  4. Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCCStatus unknownNCT03313596Study sitePhase 3Start 2013-03

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Urumqi for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

8 hospitals in Urumqi for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicinePathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 3 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 2220242025: 002025

1 hospital in Urumqi for multiple myeloma175 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDrug combinationsDiagnosis, MRD & risk

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 2 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

1 hospital in Urumqi for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesStem cell transplantInfection & supportive care
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Urumqi for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's ArteritisNot yet recruitingNCT07451665Study sitePhase 4Start 2026-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Hepatic echinococcosis

肝包虫病

Led 43 of the 152 English-language PubMed papers on hepatic echinococcosis with an author in mainland China, 2021–2025: 28.3%.

Papers led
43
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 111120212022: 4420222023: 4420232024: 131320242025: 992025

4 hospitals in Urumqi for hepatic echinococcosis44 hospitals in China for hepatic echinococcosis

No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineGastroenterology / hepatologyPediatrics
Papers it led43
  1. Ex vivo liver resection and autotransplantation for hepatic alveolar echinococcosis with cavernous transformation of the portal vein.2026Hepatobiliary & pancreatic diseases international : HBPD INT
  2. Transplantation as a treatment option for hepatic echinococcosis past, present, and future - a pooled data analysis of 476 patients.2026International journal of surgery (London, England)
  3. Exploring the mechanism and drug candidates of alveolar echinococcosis affecting liver fibrosis through analysis of existing microarray data.2025Acta tropica
  4. CT-based radiomics models using intralesional and different perilesional signatures in predicting the microvascular density of hepatic alveolar echinococcosis.2025BMC medical imaging
  5. Serum Metabolomics of Patients with Hepatic Cystic Echinococcosis.2025Biomedical chromatography : BMC
  6. Inhibition of the MyD88/NF-κB pathway alters the Th1/Th2 balance to exacerbate liver injury and hepatic fibrosis in alveolar echinococcosis.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  7. IL-22-STAT3-CD155 axis in alveolar echinococcosis: a pivotal role in immune exhaustion and therapeutic potential.2025Frontiers in immunology
  8. Hepatic alveolar echinococcosis infection induces a decrease in NK cell function through high expression of NKG2A in patients.2025Frontiers in immunology
  9. Laparoscopic procedure versus conventional cystectomy for pediatric hepatic cystic echinococcosis:a controlled clinical study.2025Langenbeck's archives of surgery
  10. Prevalence and determinants of frailty-sarcopenia comorbidity in hospitalized patients undergoing liver transplantation for hepatic echinococcosis.2025Transplant immunology
  11. Identification of key factors and explainability analysis for surgical decision-making in hepatic alveolar echinococcosis assisted by machine learning.2025World journal of gastroenterology
  12. sCD155 as a potential marker for diagnosing the vascular invasion in hepatic alveolar echinococcosis.2024Acta tropica
  13. Successful Interventional Therapy for Portal Vein Stenosis after Ex Vivo Liver Resection and Autotransplantation in End-Stage Hepatic Alveolar Echinococcosis with Cavernous Transformation.2024Annals of transplantation
  14. Treatment of Cavernous Transformation of Portal Vein Caused by Hepatic Cystic Echinococcosis Using Ex Vivo Liver Resection and Autotransplantation.2024Annals of transplantation
  15. Liver autotransplantation and atrial reconstruction on a patient with multiorgan alveolar echinococcosis: a case report.2024BMC infectious diseases
  16. Ultrasonography screening of hepatic cystic echinococcosis in sheep flocks used for evaluating control progress in a remote mountain area of Hejing County, Xinjiang.2024BMC veterinary research
  17. Applying LASSO logistic regression for the prediction of biliary complications after ex vivo liver resection and autotransplantation in patients with end-stage hepatic alveolar echinococcosis.2024European journal of medical research
  18. Portal vein embolization combined with ex vivo liver resection and autotransplantation: A novel treatment strategy for end-stage and metastatic hepatic alveolar echinococcosis.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  19. Drug repurposing for hard-to-treat human alveolar echinococcosis: pyronaridine and beyond.2024Parasitology
  20. Induced hepatocyte-like cells derived from adipose-derived stem cells alleviates liver injury in mice infected with Echinococcus Multilocularis.2024Scientific reports
  21. Efficiency of Anatomical Hepatectomy in the Treatment of Hepatic Cystic Echinococcosis.2024Surgical infections
  22. Clinical Application of Artificial Intelligence in the Ultrasound Classification of Hepatic Cystic Echinococcosis.2024The American journal of tropical medicine and hygiene
  23. Multiclassification of Hepatic Cystic Echinococcosis by Using Multiple Kernel Learning Framework and Ultrasound Images.2024Ultrasound in medicine & biology
  24. Fifty-five cases of hepatic alveolar echinococcosis combined with lymph node metastasis: A retrospective study.2024World journal of gastroenterology
  25. Multidetector computed tomography assessment of venous invasion in hepatic alveolar echinococcosis.2023Abdominal radiology (New York)
  26. Collateral circulation caused by end-stage hepatic alveolar echinococcosis.2023BMC infectious diseases
  27. Oral Delivery of Anti-Parasitic Agent-Loaded PLGA Nanoparticles: Enhanced Liver Targeting and Improved Therapeutic Effect on Hepatic Alveolar Echinococcosis.2023International journal of nanomedicine
  28. Lumbosacral Echinococcosis.2023The American journal of tropical medicine and hygiene
  29. Massive sympathetic nerve infiltration in advanced hepatic alveolar echinococcosis: a case report and review of the literature.2022BMC infectious diseases
  30. Application of hepatic lobe hyperplasia techniques in the treatment of advanced hepatic alveolar echinococcosis: a single-centre experience.2022BMC surgery
  31. Automatic Classification of Hepatic Cystic Echinococcosis Using Ultrasound Images and Deep Learning.2022Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  32. Approaches to reconstruction of inferior vena cava by ex vivo liver resection and autotransplantation in 114 patients with hepatic alveolar echinococcosis.2022World journal of gastroenterology
  33. Identification of infiltrating immune cell subsets and heterogeneous macrophages in the lesion microenvironment of hepatic cystic echinococcosis patients with different cyst viability.2021Acta tropica
  34. Quantitative evaluation of range and metabolic activity of hepatic alveolar echinococcosis lesion microenvironment using PET/CT and multi-site sampling method.2021BMC infectious diseases
  35. Double versus single T-tube drainage for frank cysto-biliary communication in patients with hepatic cystic echinococcosis: a retrospective cohort study with median 11 years follow-up.2021BMC surgery
  36. Impact of Albendazole on Cytokine and Chemokine Response Profiles in Echinococcus multilocularis-Inoculated Mice.2021BioMed research international
  37. Hepatic Alveolar Echinococcosis: Predictive Biological Activity Based on Radiomics of MRI.2021BioMed research international
  38. Single-Cell RNA Sequencing Reveals the Heterogeneity of Infiltrating Immune Cell Profiles in the Hepatic Cystic Echinococcosis Microenvironment.2021Infection and immunity
  39. Laparoscopic or open treatment for hepatic alveolar echinococcosis: A single-institution experience.2021International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  40. An improved experimental method for simultaneously isolating hepatocytes and hepatic stellate cells in mouse liver infected with Echinococcus multilocularis.2021Journal of clinical laboratory analysis
  41. Laparoscopic hepatectomy for the treatment of hepatic alveolar echinococcosis.2021Parasite (Paris, France)
  42. Use of the ligamentum teres hepatis for outflow reconstruction during ex vivo liver resection and autotransplantation in patients with hepatic alveolar echinococcosis: A case series of 24 patients.2021Surgery
  43. Feasibility of Retrohepatic Inferior Vena Cava Resection Without Reconstruction for Hepatic Alveolar Echinococcosis.2021The American surgeon
Chinese-language papers (not in the count)1
  1. [Simultaneous combined radical surgery for hepatic and renal alveolar echinococcosis: an analysis of 10 clinical cases].2021Zhonghua wai ke za zhi [Chinese journal of surgery]
Earlier papers (2016–2020)27
  1. Kupffer Cells: Important Participant of Hepatic Alveolar Echinococcosis.2020Frontiers in cellular and infection microbiology
  2. Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model.2020Hepatology (Baltimore, Md.)
  3. Left trisectionectomy and supra-hepatic caval reconstruction with vascular prosthesis for chronic Budd-Chiari syndrome caused by hepatic alveolar echinococcosis.2019Chinese medical journal
  4. Resection of retrohepatic inferior vena cava without reconstruction for hepatic alveolar echinococcosis.2019Chinese medical journal
  5. Compared efficacy of University of Wisconsin and histidine-tryptophan-ketoglutarate solutions in ex-situ liver resection and autotransplantation for end-stage hepatic alveolar echinococcosis patients.2019Hepatobiliary & pancreatic diseases international : HBPD INT
  6. Simultaneous occurrence of hepatic alveolar and cystic echinococcosis.2019Journal of helminthology
  7. Differentiation between hepatic cystic echinococcosis types 1 and simple hepatic cysts: A retrospective analysis.2019Medicine
  8. Subcutaneous Inoculation of Echinococcus multilocularis Induces Delayed Regeneration after Partial Hepatectomy.2019Scientific reports
  9. Ex vivo liver resection and autotransplantation as alternative to allotransplantation for end-stage hepatic alveolar echinococcosis.2018Journal of hepatology
  10. Quantitative characterization and diagnosis via hard X-ray phase-contrast microtomography.2018Microscopy research and technique
  11. Plasma IL-23 and IL-5 as surrogate markers of lesion metabolic activity in patients with hepatic alveolar echinococcosis.2018Scientific reports
  12. Comparison of [18F]Fluorodeoxyglucose Positron Emission Tomography and Contrast-Enhanced Ultrasound for Evaluation of Hepatic Alveolar Echinococcosis Activity.2018Ultrasound in medicine & biology
  13. Comparison of Intravoxel Incoherent Motion Diffusion-Weighted Magnetic Resonance (MR) Imaging to T1 Mapping in Characterization of Hepatic Alveolar Echinococcosis.2017Medical science monitor : international medical journal of experimental and clinical research
  14. Recurrent multiple-organ involvement of disseminated alveolar echinococcosis in 3 patients: Case report.2017Medicine
  15. Cloning and characterization of an Echinococcus granulosus ecdysteroid hormone nuclear receptor HR3-like gene.2017Parasite (Paris, France)
  16. T-cell tolerance and exhaustion in the clearance of Echinococcus multilocularis: role of inoculum size in a quantitative hepatic experimental model.2017Scientific reports
  17. Novel Interventional Management of Hepatic Hydatid Cyst with Nanosecond Pulses on Experimental Mouse Model.2017Scientific reports
  18. Molecular Cloning and Characterization of Ribosomal Protein RPS9 in Echinococcus granulosus.2017The Journal of parasitology
  19. Improved experimental model of hepatic cystic hydatid disease resembling natural infection route with stable growing dynamics and immune reaction.2017World journal of gastroenterology
  20. Ex Vivo Liver Resection and Autotransplantation for End-Stage Alveolar Echinococcosis: A Case Series.2016American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  21. Surgical Procedure Choice for Removing Hepatic Cysts of Echinococcus granulosus in Children.2016European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie
  22. Surgical treatment of hepatic cystic echinococcosis in patients co-infected with HIV/AIDS.2016Journal of helminthology
  23. Comparative Evaluation of Liposomal Albendazole and Tablet-Albendazole Against Hepatic Cystic Echinococcosis: A Non-Randomized Clinical Trial.2016Medicine
  24. Assessment of Vascularity in Hepatic Alveolar Echinococcosis: Comparison of Quantified Dual-Energy CT with Histopathologic Parameters.2016PloS one
  25. Immunological Characteristics of Recurrent Echinococcosis-Induced Anaphylactic Shock.2016The American journal of tropical medicine and hygiene
  26. [Application of three-dimensional visualization technology in surgical treatment for patients with hepatic alveolar echinococcosis].2016Zhonghua wai ke za zhi [Chinese journal of surgery]
  27. [Living donor liver transplantation for the treatment complicated hepatic cystic echinococcosis: first case report from China].2016Zhonghua yi xue za zhi

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led no English-language PubMed papers on idiopathic pulmonary fibrosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

3 hospitals in Urumqi for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Research Progress in the Pathogenesis of Idiopathic Pulmonary Fibrosis with Lung Cancer].2020Zhongguo fei ai za zhi = Chinese journal of lung cancer
All its trials on ClinicalTrials.gov, any status1
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

1 hospital in Urumqi for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Urumqi for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  2. Atrasentan in Patients With IgA NephropathyActive, not recruitingNCT04573478Study sitePhase 3Start 2020-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Urumqi for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Genotypes and phenotypes of nine Uygur children with osteogenesis imperfecta in Xinjiang].2020Zhonghua er ke za zhi = Chinese journal of pediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

1 hospital in Urumqi for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    Phase
    Phase 3
    Started
    2023-09
    Registry
    NCT06051617

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Increased expression of IL-9 in peripheral blood and liver tissues of patients with primary biliary cirrhosis].2016Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
All its trials on ClinicalTrials.gov, any status1
  1. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisRecruitingNCT06051617Study sitePhase 3Start 2023-09

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

新疆医科大学第一附属医院

First Affiliated Hospital of Xinjiang Medical University

乌鲁木齐

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
First Affiliated Hospital of XinJiang Medical University; First Affiliated Hospital of Xinjiang Medical University (XJMU); he First Affiliated Hospital of Xinjiang Medical University

Suggest a correctionDownload the data